Juno and AstraZeneca pair two hot immunotherapies in new cancer study
Juno Therapeutics and AstraZeneca are joining forces to test their respective cancer treatments in tandem, combining newfangled therapies that promise to use the immune system to combat tumors.
Almirall spares 9 jobs as ax falls on Spanish R&D operation
Almirall has confirmed it is to cut back its Spanish R&D operation as part of a move toward becoming a specialty dermatology company. But the ax-wielding is less severe than first expected, with Almirall retaining 9 of the 68 positions that were originally on the block.
Amgen, AstraZeneca prep a brodalumab pitch--after scuttling asthma program
Amgen and its partner AstraZeneca are winding up to deliver U.S. and European applications for their big blockbuster hopeful brodalumab for plaque psoriasis by midyear. But their last shot to push ahead with the drug in asthma ran into defeat, with Amgen announcing Tuesday afternoon that it pulled the plug on a Phase IIb following a futility assessment.
AstraZeneca's '$3B' lung cancer drug impresses in a Phase II race with Clovis
AstraZeneca's in-development lung cancer pill extended progression-free survival by more than a year in new Phase II data, a positive sign for a drug the company believes can bring in $3 billion in annual sales at its peak.
PatientsLikeMe adds AstraZeneca to growing list of big-name clients
PatientsLikeMe has struck a 5-year deal to support R&D at AstraZeneca. The agreement tops off a busy and important 12 months for the patient network, in which it has also expanded relationships with Biogen, Roche's Genentech and Swiss biopharma Actelion.
AZ's Onglyza should highlight heart failure risks, FDA panel advises
AstraZeneca dodged a bullet Tuesday, when an FDA panel of experts almost unanimously backed Onglyza's cardiovascular safety. But the committee did recommend that the label of the diabetes therapy feature information about a potential risk of heart failure.
Takeda, AstraZeneca diabetes drugs need warnings on heart risk, FDA says
Diabetes drugs of Takeda Pharmaceutical and AstraZeneca should be labeled at risk of heart failure associated with them, a group of U.S. FDA advisers recommended. Nearly all of the members of an advisory panel voted for the added safety information on labels.
Onglyza's label should flag heart failure risks, FDA panel says
AstraZeneca escaped the worst with an FDA panel vote on Onglyza. The agency's expert advisers almost unanimously backed the drug's cardiovascular safety. But the panel also recommended that the diabetes drug's label include information about a potential risk of heart failure.
AstraZeneca taps PatientsLikeMe's network for drug R&D insights
AstraZeneca has signed on to partner with PatientsLikeMe to cull data from its network of some 250,000 patients that will help guide drug development at the pharma giant.
AstraZeneca's Onglyza 'mortality' risks noted by FDA reviewers
FDA staff reviewers have raised serious concerns about the safety of AstraZeneca's Onglyza ahead of an advisory committee review Tuesday, which could result in a recommendation of a label change for Onglyza as well as other drugs in the DPP4 inhibitor class.